ChemoCentryx Pivotal Phase III ADVOCATE Evaluates Safety and Efficacy of Avacopan in the Treatment of ANCA-Associated Vasculitis
Patient enrollment is now complete in the Phase III ADVOCATE clinical trial of Avacopan in the treatment of patients with ANCA-associated vasculitis. The trial exceeded its 300 patient goal with 316 patients enrolled and more than 200 activated clinical sites in 20 countries worldwide.
Avacopan is an orally-administered drug candidate that inhibits the complement C5a receptor, or C5aR.
By targeting the underlying inflammatory disease process while permitting otherwise normal functioning of other components of the immune system, Avacopan may provide a basis for a totally new of way of improving ANCA-Associated Vasculitis outcomes.
The Phase III ADVOCATE trial is designed to show the effect of Avacopan on improving active vasculitis, as well as testing durable clinical benefit, which is still an unmet need in this patient population.
The ADVOCATE trial will evaluate the safety and efficacy of Avacopan following 52 weeks of treatment. Top-line data from the ADVOCATE trial is expected in the fourth quarter of 2019.
ChemoCentryx is very grateful to the patients and the dedicated clinicians who took part and are continuing to take part in this study.
